Southwestern Internal Medicine Conference: Medical management of nephrolithiasis - A new, simplified approach for general practice

American Journal of the Medical Sciences

Volumn 313, Issue 4, 1997, Pages 215-219

  Pak, Charles Y C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Medical management; Nephrolithiasis; Simplified treatment

Indexed keywords

ALLOPURINOL; CITRATE POTASSIUM; PENICILLAMINE; THIAZIDE DIURETIC AGENT; TIOPRONIN;

CALCIUM STONE; CLINICAL PROTOCOL; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; EXTRACORPOREAL LITHOTRIPSY; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; NEPHROLITHIASIS; PATHOGENESIS; STONE FORMATION; TREATMENT PLANNING; URINARY TRACT INFECTION;

EID: 0030992187     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199704000-00004     Document Type: Conference Paper

References (29)

1. Chaussy C, Schmiedt E, Brendel W. Extracorporeally induced destruction of kidney stones by shock waves. Lancet. 1980;ii:1265-8.
2. Pak CYC, Peters P, Hurt G, Kadesky M, Fine M, Reismann D, Splann F, Caramels C, Freeman A, Britton F, Sakhaee K, Breslau NA. Is selective therapy of recurrent nephrolithiasis possible? Am J Med. 1981;71:615-22.
3. Coe FL, Keck J, Norton R. The natural history of calcium urolithiasis. JAMA. 1977;238:1519-23.
4. Fine JK, Pak CYC, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol. 1995;153:27-33.
5. Pak CYC, Physiological basis for absorptive and renal hypercalciurias. Am J Physiol. 1975;237:F415-23.
6. 2D in absorptive hypercalciuria. J Clin Endocrin Metab. 1992;75:1446-52.
7. Zerwekh JE, Hughes MR, Reed BY, Breslau NA, Heller H, Lemke M, Nasonkin I, Pak CYC. Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Clin Endocrin Metab. 1995;80:2960-5.
8. Reed BY, Heller HJ, Lemke M, Lane H, Reza Albaran A, Zerwekh JE, Breslau NA, Pak CYC. Linkage analysis in absorptive hypercalciuria lack of linkage to the vitamin D receptor or 1, 25(OH)2D3 1-αhydroxylase loci. In: Pak CYC, Resnick MI, Preminger GM; eds. Urolithiasis 1996. Dallas: Millet the Printer; 1996:540-2.
9. Pak CYC. Citrate and renal calculi: an update. Miner Electrolyte Metab. 1094;20:371-7.
10. Cowley DM, McWhinney BC, Brown JM, Chalmers AH. Chemical factors important to calcium nephrolithiasis: Evidence for impaired hydroxycarboxylic acid absorption causing hyperoxaluria. Clin Chem. 1987;33:243-7.
11. Fegan J, Khan R, Poindexter J, Pak CYC. Gastrointestinal citrate absorption in nephrolithiasis. J Urol. 1992;147:1212-4.
12. Khatchadourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CYC. Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation, J Urol. 1995;154:1665-9.
13. Gitomer W, Pak CYC. Recent advances in the biochemical and molecular biological basis of cystinuria. J Urol. 1996;156:1907-12.
14. Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CYC. Potential role of salt abuse on the risk for kidney stone formation. J Urol. 1991;150:310-2.
15. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Eng J Med. 1993;328:833-8.
16. Norman DA, Fordtran JA, Brinhley LJ, Zerwekh JE, Nicar MJ, Strowig SM, Pak CYC, Jejunal and ileal adaptation to alterations in dietary calcium: changes in calcium and magnesium absorption and pathogenetic role of parathyroid hormone and 1,25-dihydroxyvitamin D. J Clin Invest. 1981;67:1599-1603.
17. Sakhaee K, Baker S, Zerwekh J, Poindexter J, Garcia-Hernandez A, Pak CYC. Limited risk of kidney stone formation during long-term calcium citrate supplementation in non-stone forming subjects. J Urol. 1994;152:324-7.
18. Pak CYC, Ohata M, Lawrence EC, Snyder W. The hypercalciurias: causes parathyroid functions and diagnostic criteria. J Clin Invest. 1974;54:387-400.
19. Wabner CL, Pak CYC. Effect of orange juice consumption on urinary stone risk factors. J Urol. 1993;149:1405-8.
20. Pak CYC, Griffith DP, Menon M, Preminger GM, Resnick RI. Urolithiasis. In: Glassock R; ed. Current Practice of Medicine Series, (ed) Bone RC volume. Philadelphia: Current Medicine Inc.; 1996;4:133-4.
21. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CYC. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150:1761-4.
22. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kid Int. 1978;13:397-409.
23. Nicar MJ, Peterson R, Pak CYC. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol. 1084;131:430-3.
24. Sullivan JM, Dluhy RG, Wacker WEC, Solomon HS, Williams GH, Samaha JK. Interrelationships among thiazide diuretics and calcium, magnesium, sodium, and potassium balance in normal and hypertensive man. J Clin Pharm. 1978;18:530-43.
25. Ettinger B, Pak CYC, Citron JT, VanGessel A. Randomized trial of potassium magnesium citrate in the prevention of recurrent calcium oxalate nephrolithiasis. In: CYC Pak, MI Resnick. GM Preminger; eds. Urolithiasis 1996. Dallas: Millet the Printer; 1996:437-9.
26. Preminger GM, Pak CYC. Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. J Urol. 1987;137:1104-9.
27. Breslau NA, Padalino P, Kok DJ, Kim YC, Pak CYC. Physicochemical effects of a new slow-release potassium phosphate preparation (UroPhos-K) in absorptive hypercalciuria. J Bone Miner Res 10:394-400, 1993.
28. Griffith DP, Musher DM. Prevention of infected urinary stones by urease inhibition. Investigative Urology. 1973;11:228-32.
29. Pak CYC, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine, (Thiola). J Urol. 1986;136:1003-8.